Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC

November 29, 2022

https://www.globenewswire.com/news-release/2022/11/29/2563860/30446/en/Aravive-Announces-Fast-Track-Designation-of-Batiraxcept-for-Treatment-of-ccRCC.html

HOUSTON, Nov. 29, 2022 (GLOBE NEWSWIRE) — Aravive, Inc. (Nasdaq:ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the company’s lead program, batiraxcept, for treatment of patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have progressed after 1 or 2 prior lines of systemic therapy that include both immuno-oncology (IO)-based and vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI)-based therapies (either in combination or sequentially).

Read more at globenewswire.com

Related news for (ARAV)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.